Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Regulatory
Approvals worldwideDrug spendingDrug targets
Regulatory · NICE technology appraisal guidance · England

NICE technology appraisals

Every medicine and treatment NICE has appraised for the NHS in England since 2000: NICE's recommendation, when it was published, whether it still stands, and a link to the guidance and to the medicine's trials on this site.

Source: NICE technology appraisal guidance and NICE's appraisal recommendations data, shown with NICE's permission. Checked 3 Oct 2026
1,189Technology appraisals published
90%Of 897 current decided appraisals recommend for at least some patients
72Published in 2026 so far
976Linked to a medicine page here
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from NICE technology appraisal guidance · Last verified · Editorial standards

NICE has published 1,189 technology appraisals since 2000, and 1,062 of them are still current. Of the current appraisals where NICE reached a decision, 90% recommend the medicine or treatment for at least some patients, including through the Cancer Drugs Fund. The most recent is TA1189, published 26 Aug 2026. NICE's decisions apply to the NHS in England; in Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics.

01

What NICE decided

Appraisals by recommendation type
Recommended or optimised
836
Cancer Drugs Fund or Innovative Medicines Fund
64
Only in research
23
Not recommended
145
Terminated (no company submission)
177

An appraisal can contain several recommendations, for different groups of patients, so it can appear under more than one type. These explanations are ours; NICE's own definitions are on nice.org.uk.

02

Recommended or optimised

836 appraisals, newest first, page 6 of 9
AppraisalMedicine pageNICE recommendationPublishedStatus
Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
NICE TA428
PembrolizumabOptimised11 Jan 2017
Updated 12 Sep 2017
Current
Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib
NICE TA427
PomalidomideRecommended11 Jan 2017Current
Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
NICE TA426
Dasatinib, Nilotinib, ImatinibRecommended21 Dec 2016Current
Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
NICE TA425
Dasatinib, Nilotinib, ImatinibOptimised Recommended Not recommended21 Dec 2016Current
Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
NICE TA424
PertuzumabRecommended21 Dec 2016Current
Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
NICE TA423
EribulinOptimised21 Dec 2016Current
Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
NICE TA422
CrizotinibRecommended21 Dec 2016Current
Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
NICE TA421
EverolimusRecommended21 Dec 2016Current
Ticagrelor for preventing atherothrombotic events after myocardial infarction
NICE TA420
TicagrelorRecommended14 Dec 2016Current
Apremilast for treating moderate to severe plaque psoriasis
NICE TA419
ApremilastRecommended23 Nov 2016Current
Dapagliflozin in triple therapy for treating type 2 diabetes
NICE TA418
—Recommended23 Nov 2016Current
Nivolumab for previously treated advanced renal cell carcinoma
NICE TA417
NivolumabRecommended23 Nov 2016Current
Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor
NICE TA415
Certolizumab PegolOptimised26 Oct 2016Current
Elbasvir–grazoprevir for treating chronic hepatitis C
NICE TA413
—Recommended26 Oct 2016Current
Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases
NICE TA412
—Optimised28 Sep 2016Current
Talimogene laherparepvec for treating unresectable metastatic melanoma
NICE TA410
Talimogene LaherparepvecOptimised28 Sep 2016Current
Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
NICE TA409
AfliberceptRecommended28 Sep 2016Current
Pegaspargase for treating acute lymphoblastic leukaemia
NICE TA408
PegaspargaseOptimised28 Sep 2016Current
Secukinumab for treating active ankylosing spondylitis
NICE TA407
SecukinumabRecommended28 Sep 2016Current
Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
NICE TA406
CrizotinibRecommended28 Sep 2016Current
Trifluridine–tipiracil for previously treated metastatic colorectal cancer
NICE TA405
—Recommended24 Aug 2016Current
Degarelix for treating advanced hormone-dependent prostate cancer
NICE TA404
DegarelixOptimised24 Aug 2016Current
Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin
NICE TA402
PemetrexedRecommended24 Aug 2016Current
Bosutinib for previously treated chronic myeloid leukaemia
NICE TA401
BosutinibRecommended24 Aug 2016Current
Nivolumab in combination with ipilimumab for treating advanced melanoma
NICE TA400
NivolumabRecommended27 Jul 2016Current
Belimumab for treating active autoantibody-positive systemic lupus erythematosus
NICE TA397
BelimumabOptimised22 Jun 2016Current
Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
NICE TA396
TrametinibRecommended22 Jun 2016Current
Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
NICE TA395
CeritinibRecommended22 Jun 2016Current
Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
NICE TA394
EvolocumabOptimised22 Jun 2016Current
Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
NICE TA393
AlirocumabOptimised22 Jun 2016Current
Adalimumab for treating moderate to severe hidradenitis suppurativa
NICE TA392
AdalimumabRecommended22 Jun 2016Current
Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
NICE TA391
CabazitaxelRecommended25 May 2016
Updated 24 Aug 2016
Current
Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
NICE TA390
Canagliflozin, DapagliflozinOptimised25 May 2016Current
Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
NICE TA389
Paclitaxel, Pegylated liposomal doxorubicin, Gemcitabine, Trabectedin, TopotecanRecommended Not recommended27 Apr 2016Current
Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction
NICE TA388
Sacubitril / ValsartanOptimised27 Apr 2016Current
Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
NICE TA387
Abiraterone acetateRecommended27 Apr 2016
Updated 27 Jul 2016
Current
Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
NICE TA386
RuxolitinibOptimised23 Mar 2016Current
Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia
NICE TA385
EzetimibeRecommended24 Feb 2016Current
Nivolumab for treating advanced (unresectable or metastatic) melanoma
NICE TA384
NivolumabRecommended18 Feb 2016Current
TNF-alpha inhibitors for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis
NICE TA383
Adalimumab, Certolizumab Pegol, Etanercept, Golimumab, InfliximabRecommended1 Feb 2016Current
Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy
NICE TA381
OlaparibOptimised27 Jan 2016Current
Panobinostat for treating multiple myeloma after at least 2 previous treatments
NICE TA380
—Recommended27 Jan 2016Current
Nintedanib for treating idiopathic pulmonary fibrosis
NICE TA379
NintedanibOptimised27 Jan 2016Current
Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
NICE TA377
EnzalutamideRecommended27 Jan 2016Current
Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases
NICE TA376
—Optimised27 Jan 2016Replaced by TA412
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
NICE TA375
Adalimumab, Etanercept, Infliximab, Certolizumab Pegol, Golimumab, Tocilizumab, AbataceptOptimised26 Jan 2016Current
Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
NICE TA374
Erlotinib, GefitinibOptimised Not recommended16 Dec 2015Current
Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
NICE TA373
Abatacept, Adalimumab, Etanercept, TocilizumabRecommended16 Dec 2015Current
Bortezomib for previously untreated mantle cell lymphoma
NICE TA370
BortezomibRecommended16 Dec 2015Current
Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears
NICE TA369
CiclosporinRecommended16 Dec 2015Current
Vortioxetine for treating major depressive episodes
NICE TA367
VortioxetineRecommended25 Nov 2015Current
Pembrolizumab for advanced melanoma not previously treated with ipilimumab
NICE TA366
PembrolizumabRecommended25 Nov 2015
Updated 12 Sep 2017
Current
Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
NICE TA365
RitonavirRecommended25 Nov 2015Current
Daclatasvir for treating chronic hepatitis C
NICE TA364
—Optimised25 Nov 2015Withdrawn
Ledipasvir–sofosbuvir for treating chronic hepatitis C
NICE TA363
—Optimised25 Nov 2015Current
Idelalisib for treating chronic lymphocytic leukaemia
NICE TA359
IdelalisibRecommended28 Oct 2015Current
Tolvaptan for treating autosomal dominant polycystic kidney disease
NICE TA358
TolvaptanOptimised28 Oct 2015Current
Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
NICE TA357
PembrolizumabRecommended7 Oct 2015
Updated 12 Sep 2017
Current
Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation
NICE TA355
EdoxabanRecommended23 Sep 2015
Updated 2 Jul 2021
Current
Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism
NICE TA354
EdoxabanRecommended26 Aug 2015Current
Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy
NICE TA352
VedolizumabOptimised26 Aug 2015Current
Secukinumab for treating moderate to severe plaque psoriasis
NICE TA350
SecukinumabRecommended22 Jul 2015Current
Dexamethasone intravitreal implant for treating diabetic macular oedema
NICE TA349
DexamethasoneOptimised22 Jul 2015Replaced by TA824
Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer
NICE TA347
NintedanibRecommended22 Jul 2015Current
Aflibercept for treating diabetic macular oedema
NICE TA346
AfliberceptOptimised22 Jul 2015Current
Naloxegol for treating opioid‑induced constipation
NICE TA345
—Recommended22 Jul 2015Current
Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia
NICE TA344
OfatumumabRecommended2 Jun 2015Withdrawn
Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia
NICE TA343
ObinutuzumabOptimised2 Jun 2015Current
Vedolizumab for treating moderately to severely active ulcerative colitis
NICE TA342
VedolizumabRecommended5 Jun 2015Current
Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
NICE TA341
ApixabanRecommended4 Jun 2015Current
Ustekinumab for treating active psoriatic arthritis
NICE TA340
UstekinumabOptimised4 Jun 2015
Updated 3 Mar 2017
Current
Omalizumab for previously treated chronic spontaneous urticaria
NICE TA339
OmalizumabOptimised8 Jun 2015Current
Rifaximin for preventing episodes of overt hepatic encephalopathy
NICE TA337
RifaximinRecommended25 Mar 2015Current
Empagliflozin in combination therapy for treating type 2 diabetes
NICE TA336
—Recommended25 Mar 2015Current
Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome
NICE TA335
RivaroxabanRecommended25 Mar 2015Current
Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment
NICE TA333
AxitinibRecommended25 Feb 2015Current
Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C
NICE TA331
—Recommended25 Feb 2015Current
Sofosbuvir for treating chronic hepatitis C
NICE TA330
—Optimised25 Feb 2015Current
Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
NICE TA329
Infliximab, Adalimumab, GolimumabRecommended25 Feb 2015Current
Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
NICE TA327
Dabigatran EtexilateRecommended17 Dec 2014Current
Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
NICE TA326
ImatinibRecommended26 Nov 2014Current
Nalmefene for reducing alcohol consumption in people with alcohol dependence
NICE TA325
—Recommended26 Nov 2014Current
Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block
NICE TA324
—Recommended26 Nov 2014Current
Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy
NICE TA323
—Recommended26 Nov 2014Current
Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality
NICE TA322
LenalidomideRecommended24 Sep 2014
Updated 26 Jun 2019
Current
Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma
NICE TA321
DabrafenibRecommended22 Oct 2014Current
Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis
NICE TA320
Dimethyl FumarateRecommended27 Aug 2014Current
Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
NICE TA319
IpilimumabRecommended23 Jul 2014Current
Lubiprostone for treating chronic idiopathic constipation
NICE TA318
LubiprostoneRecommended23 Jul 2014Withdrawn
Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes
NICE TA317
PrasugrelRecommended23 Jul 2014Current
Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen
NICE TA316
EnzalutamideRecommended23 Jul 2014Current
Canagliflozin in combination therapy for treating type 2 diabetes
NICE TA315
CanagliflozinRecommended25 Jun 2014Current
Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure
NICE TA314
—Optimised25 Jun 2014Current
Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis
NICE TA312
AlemtuzumabRecommended28 May 2014
Updated 21 May 2024
Current
Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation
NICE TA311
BortezomibRecommended23 Apr 2014Current
Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
NICE TA310
AfatinibRecommended23 Apr 2014Current
Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis
NICE TA308
RituximabOptimised26 Mar 2014Current
Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphoma
NICE TA306
—Optimised26 Feb 2014Current
Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion
NICE TA305
AfliberceptRecommended26 Feb 2014Current
Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hip
NICE TA304
—Recommended26 Feb 2014Current

Titles link to the guidance on nice.org.uk, where the full recommendations are. A medicine is linked to its page here only when the name NICE appraised is exactly the same molecule as ours; medicines given alongside it (“with chemotherapy”) are not counted as appraised. Appraisals of devices and procedures are listed but have no medicine page.

© NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Medicines data, weekly

One email every Friday: new approvals, trials and shortages, with every figure linked to its source.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

NICE has allowed us to show the appraisal number, title, recommendation category and dates of each technology appraisal, with a link to the guidance. No guidance text is reproduced.

A nightly job reads NICE's recommendations data, reads each new appraisal page once and re-checks every page every 60 days for replaced or withdrawn guidance. It keeps the previous version if a refresh fails. No AI drafting. See our methodology. The NICE data on this page was last retrieved on 3 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.